(VIANEWS) – Shares of Castle Biosciences (NASDAQ: CSTL) fell 9.52% to $21.96 at 12:15 EST on Friday, after two successive sessions in a row of losses. NASDAQ is jumping 1.19% to $10,465.74, after four consecutive sessions in a row of losses. This seems, up to now, an all-around bullish trend trading session today.

Castle Biosciences’s last close was $24.27, 63.06% below its 52-week high of $65.71.

About Castle Biosciences

Castle Biosciences, Inc. is a diagnostics company in the commercial stage. It specializes in providing diagnostic and prognostic services for dermatological carcinomas. DecisionDx-Melanoma is the company’s flagship product. This multi-gene expression profil (GEP test) identifies patients with invasive skin melanoma at risk for metastasis. DecisionDx UM, a proprietary GEP testing that determines the likelihood of metastasis in patients suffering from uveal melanoma (a rare form of eye cancer), DecisionDx SCC (a 40-gene expression profil test that analyzes a patient’s tumor biology and predicts individual risk for squamous cells carcinoma metastasis) and DecisionDx DiffDx -Melanoma. The company offers testing services to physicians as well as their patients. It was established in Texas in 2007.

Earnings Per Share

As for profitability, Castle Biosciences has a trailing twelve months EPS of $-1.24.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -12.66%.

Annual Top and Bottom Value

Castle Biosciences’ stock was valued at $21.96 as of 12:16 EST. This is way lower than its 52 week high of $65.71 but way higher than its 52-week low at $15.58.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Castle Biosciences’s stock is considered to be overbought (>=80).

Revenue Growth

Year-on-year quarterly revenue growth grew by 17.7%, now sitting on 98.12M for the twelve trailing months.

Moving Average

Castle Biosciences’s value is way under its 50-day moving average of $26.45 and way below its 200-day moving average of $29.76.

More news about Castle Biosciences (CSTL).